The present study aimed at investigating the effectiveness and tolerability of bupropion
hydrochloride extended release (XL) in major depressive disorder (MDD) patients with …

Background Patients with treatment-resistant major depressive disorder (MDD) remain a
common clinical challenge. Methods This 6-week, randomised, open-label, rater-blinded …

Several drugs previously tested in clinical trials and approved for different indications have
been repurposed for bipolar disorder. We carried out a systematic meta-review of meta …

The American Psychiatric Association (APA) updated their practice guideline for major
depressive disorder (MDD) in November 2010. The work group underscored the importance …

The aim of this study was to confirm the efficacy and tolerability of Quetiapine XR as
monotherapy in the treatment of Major Depressive Disorder (MDD) and determine the …

Abstracts from the XXVI CINP Congress, Munich, 13–17 July 2008 Page 1 P-04. Affective
Disorders, clinical 185 Conclusion: Quetiapine XR (400–800 mg) once daily monotherapy was …

Objective: To evaluate the efficacy and tolerability of once-daily extended release quetiapine
fumarate (quetiapine XR) as monotherapy treatment for major depressive disorder (MDD) …

Background Placebos prescribed as 'regular'medication can reduce symptoms of
depression. However, using a placebo without patients' informed consent presents ethical …

Identification of predictors of treatment response in patients with major depressive disorder
(MDD) may facilitate improved disease management. Data were pooled from two 6-week …

Objective: To review the clinical data investigating the efficacy and safety of quetiapine in
bipolar depression. Data Sources: Searches of MEDLINE and PubMed (1977–July 2009) …